Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Reflections on the AGM

<< Previous

Bullboard Posts

Next >>

Comment by Lesalpes29on May 17, 2024 7:22am

135 Views

Post# 36044917

RE:Reflections on the AGM

If I understand the last developments we are in for an other year of slow progress. Difficult to see any buyout this year without a partnership with $ sign in the next 2-3 months. Patience is getting shorter but we have some positives posters maybe they will be right one day!

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China